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Perioperative chemotherapy more 
of a benefit for overall survival 
than adjuvant chemotherapy 
for operable gastric cancer: an 
updated Meta-analysis
Ya’nan Yang1,*, Xue Yin1,*, Lei Sheng2,*, Shan Xu1, Lingling Dong3 & Lian Liu1
To clarify the effect of neoadjuvant chemotherapy (NAC) on the survival outcomes of operable gastric 
cancers, we searched PubMed, Embase, and Cochrane Library for randomized clinical trials published 
until June 2014 that compared NAC-containing strategies with NAC-free strategies in patients with 
adenocarcinoma of the stomach or the esophagogastric junction, who had undergone potentially 
curative resection. The adjusted pooled hazard ratio (HR) for overall survival (OS) was insignificant 
when comparing the NAC-containing arm with the NAC-free arm. Subgroup analysis showed that the 
OS of the treatment arm that involved both adjuvant chemotherapy (AC) and NAC was significantly 
improved over the control arm (AC only) (HR = 0.48, 95% CI: 0.35–0.67; P < 0.001). While NAC alone 
plus surgery did not show any survival benefit over surgery alone. Perioperative chemotherapy (PC) 
also showed a significant increase in PFS and a significant reduction in distant metastasis compared 
to surgery alone. Therefore, in patients with resectable gastric cancer, NAC alone is not enough and 
AC alone is not good enough to definitely improve their OS. Collectively, PC combined with surgery 
could maximize the survival benefit for patients with resectable gastric cancer.
Although there has been a decline in the incidence and mortality of gastric cancer in the past few years, 
this form of cancer remains a common and very fatal disease and is still the second leading cause of 
cancer-related deaths worldwide1. The general prognosis for gastric cancer is poor, and the 5-year survival 
rate is less than 20%2. This might result not only from the difficulty in making an early diagnosis but also 
from the high rate of recurrence and metastasis. At present, surgery is still the only curative treatment for 
gastric cancer. However, relapse and metastasis still tend to occur in 40%–60% of cases, even after an R0 
gastrectomy3,4. To overcome the limitations of surgery in improving the prognosis of gastric cancer, peri-
operative therapies, which include pre- or postoperative chemotherapy or radiotherapy, have been stud-
ied and given much attention in recent years. Based on several multicenter, randomized controlled trials 
(RCTs), different perioperative treatments have been used in different geographic regions. According 
to the results of the Adjuvant Chemotherapy Trial ACTS-GC5,6 and CLASSIC7, adjuvant chemotherapy 
(AC) has been widely used following D2 gastrectomy in East Asia, where there is a high incidence of 
gastric cancer. In the US, chemoradiotherapy has been recommended to treat locally advanced gastric 
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cancer based on the US Intergroup-0116 trial4. In parts of Europe, perioperative chemotherapy (PC) is 
regarded as the standard treatment on the basis of the MAGIC trial3.
Although different perioperative therapies are used in different regions according to relevant RCTs 
with regional differences, the effects on improving the survival of gastric cancer patients remain limited. 
Neoadjuvant chemotherapy (NAC) was once considered a strategy that might have survival benefits in 
patients with locally advanced gastric cancer. However, in contrast to AC, which has been widely recom-
mended, NAC has been found to be successful only in combination with AC (i.e. PC) in Europe3,8. Thus, 
the role of NAC in gastric cancer is still controversial. To date, most clinical trials or meta-analyses have 
shown that NAC can improve the R0 resection rate in patients with locally advanced gastric cancer, but 
the results regarding long-term efficacy such as overall survival (OS) and progression-free survival (PFS) 
have been inconsistent9–12. Furthermore, there were some defects in these meta-analyses, such as using 
odds ratio (OR) instead of hazard ratio (HR) to estimate long-term survival effect, combining trials with 
great heterogeneity, including unqualified trials, lack of quality evaluation, and inclusion of non-random 
controlled trials, all of which made the conclusions less reliable.
Would NAC alone have survival benefits for operable gastric cancer patients, or should it be com-
bined with AC? Or is AC itself sufficient to improve the survival in gastric cancer patients and NAC is 
not useful? How do we look upon the use of NAC in Asia where the highest incidence of gastric cancer, 
skillful operative technique, and good adjuvant treatment strategies coexist? The key question is that we 
still don’t know if PC exactly has an extra advantage than AC in the treatment of operable gastric can-
cers. To address these questions, we performed an updated meta-analysis involving 2,093 patients from 
14 different trials between 1966 and June, 2014, comparing NAC-containing strategies with NAC-free 
strategies, mainly in terms of OS of patients with resectable gastric cancer, estimated by HR and 95% CI.
Methods
Literature Search. We searched PubMed, Embase, ASCO and ESMO meeting abstracts, and 
Cochrane Library by computer for randomized clinical trials published until June 2014 that compared 
NAC-containing strategies with NAC-free strategies in patients with histologically proven adenocarci-
noma of the stomach or the esophagogastric junction, who had undergone potentially curative resection. 
The search used the following key words: stomach cancer, gastric cancer, stomach tumor, gastric tumor, 
stomach neoplasm, gastric neoplasm, neoadjuvant chemotherapy, preoperative chemotherapy, primary 
chemotherapy, neoadjuvant treatment, neoadjuvant therapy, primary treatment, preoperative treatment, 
primary therapy, and preoperative therapy. The search term for MEDLINE was as follows: (resect* OR 
operative) AND ((treatment OR therapy OR chemotherapy) AND (neoadjuvant OR preoperat* OR peri-
operat*) AND (tumor OR tumour OR neoplas* OR cancer OR carcinoma) AND (gastric OR stomach 
OR esophag*)). Relevant articles and abstracts were reviewed, and the reference lists from these sources 
were searched for additional trials. Where results were reported or updated in more than one publication, 
only the most recent publication was used. There was no language restriction.
Data extraction. Two authors extracted the outcome data independently using a pre-designed data 
extraction form. Authors, year of publication, country of patients, sample size (per arm), chemotherapy 
regimen, surgical procedure, follow-up period, treatment effect (OS, PFS, survival rate, rate of macro-
scopic radical resection, tumor stage at pathological examination, local regional recurrence, and dis-
tant metastasis), and adverse events (postoperative morbidity and mortality) of each eligible trial were 
recorded. The last name of the author was used to represent the corresponding study. If more than two 
authors had the same last name, the initial of the first name was added to make a distinction.
Statistical analysis. The primary endpoints of this meta-analysis were OS (the time from random 
assignment to the last follow-up or death) and PFS (the time from random assignment to objective 
tumor progression or death) or disease-free survival (DFS: the time from random assignment to tumor 
recurrence or death). Secondary endpoints were R0 (margin negative) resection rate or curative resection 
rate, down-staging effect, incidence of recurrence, 5-year survival rate, and postoperative morbidity and 
mortality.
Results regarding OS and PFS were expressed as HR with 95% CIs, which were used directly or 
estimated from the Kaplan-Meier survival curves or by the indirect method described by Parmer and 
colleagues13. The results for the 5-year survival rate, R0 resection rate, postoperative morbidity and mor-
tality, incidence of recurrence, and metastasis, were expressed as relative risk (RR) and CIs. Moreover, to 
assess the down-staging effect of NAC (that is, the probability of having a less advanced stage of the dis-
ease at pathological examination at the time of surgery), we separated patients with negative nodes from 
those with positive nodes on pathological examination after surgery. Also, the percentage of patients 
in primary tumor stage T0-2 was calculated. All analyses were carried out based on the intent-to-treat 
principle except where only evaluable patients’ data were available.
χ 2 tests were performed to study heterogeneity between trials, and the I2 statistic was used to estimate 
the percentage of total variation across studies. Heterogeneity was considered for an I2 statistic greater 
than 50% or a P-value for the Q-test of less than 0.1. In the present meta-analysis, the results using the 
random-effect model are presented to take into account the possible clinical diversity and methodolog-
ical variation among the studies. The number needed to treat (NNT) was applied for outcomes with 
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a statistical difference. Publication bias was checked by visual inspection of contour-enhanced funnel 
plots14 and Egger’s test15 with the slope of the regression (bias coefficient) indicating the extent of any 
bias. All P-values were two-sided and P < 0.05 was considered significant. All statistical analyses were 
performed with the Stata statistical software package (release 12·0; Stata Corporation, College Station, 
TX, USA).
Results
Study selection and characteristics of included studies. Figure 1 shows the flow of the trial selec-
tion process. In brief, 4,266 studies were identified from the searches and 14 trials were included in the 
meta-analysis after the abstracts and full texts had been screened finally. The 2,093 gastric cancer patients 
who had been enrolled were placed in the NAC group (n = 952) or the control group (n = 1,141). Table 1 
shows the characteristics of the 14 trials included in the analysis. We divided them into four categories 
based on the therapeutic strategy: (1) NAC plus surgery in the treatment arm compared with surgery 
only in the control arm16–20; (2) PC plus surgery in the treatment arm compared with AC following sur-
gery in the control arm21–25; (3) PC plus surgery in the treatment arm compared with surgery only in the 
control arm3,26,27 and (4) NAC plus surgery in the treatment arm compared with AC following surgery in 
the control arm28. It should be noted that the term “NAC arm” is used hereafter to stand for interventions 
containing NAC in the treatment arm, and this refers to both category 1 and 2 above.
Quality assessment of included trials. The methodological quality of each study that was included 
was assessed according to the Cochrane Handbook for Systematic Review of Interventions 5.1.0.29 for the 
following six requirements: the method of randomization, allocation concealment, blindness, selective 
reporting, baseline, and completeness of follow-up. Five studies were graded A (low risk of bias), eight 
studies were graded B (moderate risk of bias), and one study was graded C (high risk of bias) (Table 2).
Overall survival. The HR and 95% CIs of OS could be obtained directly3,20,24,25,27 or indirectly19,22 in 
seven of the eight full-text articles investigating NAC in operable gastric cancer patients. The adjusted 
pooled estimate of the treatment effect appeared to be statistically significant (adjusted HR for death, 
0.70; 95% CI: 0.55–0.88; P = 0.003; Fig. 2A). However, the therapeutic strategies in the seven trials varied 
Figure 1. Flow diagram showing inclusion and exclusion of studies. 
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Neoadjuvant chemotherapy plus surgery vs. Surgery 
Masuyama M, 
199416 Japan 24/74 EAP-II
[1] — — — — — — —
Kobayashi O, 
199417 Japan 47/125 Aclarubicin
[2] D2 — II/III — — — 59.6%/48.0%
Wang X, 
200018 China 30/30 FPLC
[3] — — — 60 — — 40.0%/23.3%
Hartgrink H, 
200419 Netherlands 29/30 FAMTX
[4] D1 stomach II/III 83 1.51  (0.84, 2.74)** — 20.7%/33.3%
Schuhmacher 
C, 201020 Germany 72/72 FP








Perioperative chemotherapy plus surgery vs. surgery plus adjuvant chemotherapy
Kang Y, 199621 South Korea 53/54 PEF[6] PEF[7] PEF — — — — — — —
Yonemura Y, 
199322 Japan 29/26 PMUE
[8] PMUE[8] PMUE D2, D3 stomach IV 24 0.49  (0.25, 0.94)** — —
Kobayashi T, 
200023 Japan 91/80 5′ -DFUR
[9] 5′ -DFUR + MMC[10] 5′ -DFUR + MMC — — — — — — 63.7%/65.0%




D2 (150) — I~IV 83
0.53  
(0.33, 0.86) — —
Qu J, 201025 China 39/39 PTX + FOLFOX4[13] PTX + FOLFOX4 or ECF[14]
PTX + FOLFOX4 
or ECF —
stomach/
EGJ II/III  ≥ 48 — — —
Perioperative chemotherapy plus surgery vs. Surgery
Lygidakis N, 
199926 Greece 39/19 FAM
[15] FAM[15] — — — — — — —
Cunningham 
D, 20063 UK 250/253 ECF















— 68.4 0.69  (0.50, 0.95)
0.65  
(0.48, 0.89) —
Neoadjuvant chemotherapy plus surgery vs. surgery plus adjuvant chemotherapy
Biffi R, 201028 Italy 34/35 TCF[19] TCF[20] D1, D2 or D3 stomach
IB/II/
III — — — —
Table 1. Characteristics of all the trials included in the meta-analysis. *EGJ refers to esophagogastric 
junction. **Data were extracted from the Kaplan-Meier curves. [1] Etoposide 100 mg, Epirubicin 20 mg, 
Carboplatin 100 mg; intra-arterial injection. [2] Medicinal lymph node dissection using aclarubicin adsorbed 
onto activated carbon. [3] Fluorouracil polyphase liposome composite. [4] Methotrexate 1,500 mg/m2, d2; 
5-fluorouracil (5-FU) 1,500 mg/m2, d2; Leucovorin 30 mg, d3-d4; Doxorubicin 30 mg/m2, d15; every 4 
weeks,  ≤ 4 cycles. [5] Cisplatin 50 mg/m2, d1, d15, d29; d-L-folinic acid 500 mg/m2, d1, d8, d15, d22, d29, 
d36; Fluorouracil 2,000 mg/m2, d1, d8, d15, d22, d29, d36; every 48 days, 2 cycles. [6] Cisplatin 20 mg/m2 
iv d1–d5; VP16 100 mg/m2 iv d1, d3, d5; 5-FU 800 mg/m2 iv 12 h infusion d1–d5, repeated every 3 weeks. 
[7] The same regimen as no. 6; 3 cycles for curative resection and 6 cycles for non-curative resection. [8] 
Cisplatin 75 mg/m2, d1; Mitomycin-C 10 mg, d1; Etoposide 50 mg, d3–d5; every 3 weeks; UFT 400 mg 
daily. [9] 5′ -DFUR 610 mg/m2/day, po ≥ 10 d. [10] MMC, iv, d1, d2; 5′ -DFUR, po for 2 years. [11] UFT 
6–8 mg/kg/day orally within 1 h after meals. [12] Stage I–III: UFT for 1–3 years; Stage IV: 1–4 courses of 
CDDP, 5-FU and Epirubicin (EPI) (FPEPIR regimen) and then oral UFT daily. [13] Paclitaxel 135 mg/
m2, d1; Oxaliplatin 85 mg/m2, d1; Leucovorin 200 mg/m2, d1, d2; 5-FU 400 mg/m2, iv d1, d2; 600 mg/m2, 
civ 22 h, d1, d2; every 2 weeks, 3 cycles. [14] PTX + FOLFOX4: the same as no. 13. If disease progressed, 
ECF for 3 cycles. [15] Mitomycin-C, 5-FU, Leucovorin, and Farmorubicin, 10 days before surgery. [16] 
Epirubicin 50 mg/m2, d1; Cisplatin 60 mg/m2, d1; Fluorouracil 200 mg/m2, d1–d21. [17] 5-FU 800 mg/m2, 
d1–5; Cisplatin 100 mg/m2, d1; every 28 days, 2–3 cycles. [18] The same regimen as no. 17, 3–4 cycles. [19] 
Docetaxel 75 mg/m2, d1; Cisplatin 75 mg/m2, d1; 5-FU 300 mg/m2, d1–d14; every 3 weeks, 2–4 cycles. [20] 
The same regimen as [19], 4 cycles.
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geographically to some extent. Only two trials19,20 focused primarily on NAC alone with the treatment 
arm receiving NAC plus surgery and the control arm receiving surgery alone. Trials by Nio24, Yonemura22, 
and Qu25 had PC (i.e. NAC and AC) plus surgery in the treatment arm and AC following surgery in 
the control arm. Because the only variation was whether or not NAC was performed, these three trials 
were regarded as being qualified in evaluating the effect of NAC and had been combined with the two 
trials above. However, the rest two trials3,27 compared the effects of PC plus surgery and surgery alone. 
It was impossible to determine the relative contribution of NAC regarding survival benefit. As shown in 
Fig. 2A, the pooled HR for OS in these two trials was 0.72 (95% CI: 0.60–0.87; P = 0.001), revealing a 
substantial survival benefit. Considering the high weight of these two trials in this meta-analysis (43%), 
the evaluation of the effect of NAC was interfered with by the performance of AC. Therefore, we excluded 
these two trials and combined the other five trials. The pooled, adjusted estimate of the treatment effect 
then became insignificant (HR = 0.68; 95% CI: 0.44–1.05; P = 0.08; Fig. 2B), although there was a trend 
toward favoring NAC. In addition, exclusion of the study24 with high risk of bias doesn’t have significant 
impact on the pooled estimate of the treatment effect (HR = 0.74; 95% CI: 0.41–1.25; P = 0.248).
Then we performed a subgroup analysis of these five trials based on whether or not AC had been 
given. The pooled HR for the three trials22,24,25 that involved AC in both the treatment arm and the 
control arm was 0.48 (95% CI: 0.35–0.67; P < 0.001; Fig.  2B) indicating that the OS of the treatment 
arm (PC and surgery) had a significant benefit than that of the control arm (AC and surgery). When 
the study24 having high risk of bias was omitted, the pool HR for the rest of two trials22,25 remained sig-
nificant (HR = 0.45; 95% CI: 0.28–0.70; P = 0.001). In the other two trials without AC in the treatment 
and control arms, NAC plus surgery did not give any survival benefit over surgery alone (Fig. 2B). By 
coincidence, the three trials comparing PC with AC were all conducted in Asian countries (China and 
Japan) while the other two comparing NAC with surgery were both conducted in European countries 
(the Netherlands and Germany). Another subgroup analysis was performed to evaluate the different 
regimens used in NAC. The platinum-containing regimens showed better efficacy in improving OS than 
other regimens (Fig. 2C).
Progression-free survival. For PFS, data could be extracted from the descriptions of three RCTs, 
including the two comparing PC with surgery and an EORTC40954 trial comparing NAC with surgery 
alone. The results of the perioperative subgroup showed a significant increase in PFS3,27. The HR of 0.66 
(95% CI: 0.55–0.78; P < 0.001) represented a 34% overall relative reduction in the risk of disease pro-
gression from PC. There appeared to be no potential survival benefit in the EORTC40954 trial, which 
only performed NAC in the treatment arm (Fig. 2D)20.
R0 resection rate. The R0 resection rate for gastric cancer was reported in eight trials. It was higher 
for the NAC group than for the control group (72.9% vs. 65.6%) with an RR of 1.11 (95% CI: 1.04–1.20; 
P = 0.003; Fig. 3A). Subgroup analysis revealed that in the Asian group the R0 resection rate in the NAC 
arm was higher than that in the control arm (66.1% vs. 50.4%) and reached statistical significance with a 
pooled RR of 1.33 (95% CI: 1.08–1.64; P = 0.007; NNT = 7; Fig. 3A)21,22,25. In non-Asian groups, the R0 










Cunningham D3 By data center By phone call No details Well reported Not mentioned Identical baseline A
Masuyama M16 No details No details No details Not mentioned Not mentioned Not mentioned B
Kobayashi O17 No details No details No details Not mentioned Not mentioned Not mentioned B
Wang X18 No details No details No details Well reported Not mentioned Not mentioned B
Hartgrink H19 By data center By phone call No Well reported Not mentioned Identical baseline A
Schuhmacher C20 No details No details No details Well reported Not mentioned Different performance status B
Kang Y21 No details No details No details Not mentioned Not mentioned Not mentioned B
Yonemura Y22 Well reported Sealed envelope No Well reported Not mentioned Identical baseline A
Kobayashi T23 No details No details No details Not mentioned Not mentioned Not mentioned B
Nio Y24 Single-consent No No Well reported Not mentioned Different stage and histological grade C
Qu J25 Random digits table No details No details Well reported Not mentioned Identical baseline A
Lygidakis N26 No details No details No details Not mentioned Not mentioned Not mentioned B
Ychou M27 Central randomization By phone call No details Well reported Not mentioned Identical baseline A
Biffi R28 No details No details No details Well reported Not mentioned Identical baseline B
Table 2.  Quality assessment of the studies included.
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statistical significance (RR = 1.08, 95% CI: 1.00–1.16; P = 0.059; NNT = 19; Fig.  3A), there was still a 
trend indicating the effectiveness of NAC in improving R0 resection rate.
Down-staging effect. A total of eight RCTs involving 1,905 patients were available for evaluation of 
the down-staging effect of NAC (Fig. 3B). The percentage of patients achieving negative lymph node status 
was 25.2% in the NAC group and 18.5% in the control group (RR = 1.39; 95% CI: 1.03–1.89; NNT = 15; 
P = 0.033)3,19–21,27. Similar results were obtained when a fixed-effect model was used (RR = 1.37; 95% CI: 
1.09–1.73; P = 0.007). Furthermore, the rate of T0-2 was higher for the NAC group than for the control 
group (40.5% vs. 30.3%), with an RR of 1.34 (95% CI: 1.12–1.60; P = 0.001) and an NNT of 103,20,27.
Five-year Survival Rate. Four studies compared the 5-year survival rate in the two arms. The pooled 
data showed no significant increase in 5-year survival rate of 52.8% (104/197) in the NAC arm and 48.7% 
(129/265) in the control arm (RR = 1.08, 95% CI: 0.90–1.28; P = 0.406). Among these, three trials used 
NAC plus surgery in the treatment arm and surgery alone in the control arm and one trial performed 
PC plus surgery in the treatment arm and AC following surgery in the control arm, so separate analyses 
were conducted. The results showed that neither the three AC-free trials (RR = 1.18; 95% CI: 0.90–1.56; 
P = 0.221) nor the AC-containing trial (RR = 0.98, 95% CI: 0.78–1.23; P = 0.863) showed any statistical 
significance, and this indicated that NAC alone might not suffice to improve the 5-year survival rate of 
resectable gastric cancer (Supplemental Fig. 1).
Figure 2. Overall HR for survival outcomes of resectable gastric cancers when comparing NAC-
containing arm and NAC-free arm. (A) Forest plot showing the OS of resectable gastric cancer patients 
in the seven NAC-containing RCTs. (B) Forest plot showing the OS of resectable gastric cancer patients 
in the five NAC-containing RCTs subgrouped by therapeutic strategies. (C) Forest plot showing the OS 
of resectable gastric cancer patients in the five NAC-containing RCTs subgrouped by whether or not the 
regimen contained platinum. (D) Forest plot showing the PFS of resectable gastric cancer patients in 
three NAC-containing RCTs. HR, hazard ratio; 95% CI, 95%confidence interval; OS, overall survival; PFS, 
progression-free survival; NAC, neoadjuvant chemotherapy; AC, adjuvant chemotherapy; S, surgery; RCTs, 
randomized controlled trials.
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Postoperative Morbidity and Mortality. From five trials, the incidence of overall postoperative 
morbidity was reported as 34.0% (172/506) in the NAC group and 30.8% (157/510) in the surgery alone 
group, but this difference between the two arms was not significant (RR = 1.11, 95% CI: 0.93–1.31; 
P = 0.24). Similar results were obtained when a random effect model was used (RR = 1.08, 95% CI: 0.91–
1.28; P = 0.38). The incidence rate of postoperative mortality reported from six studies was 5.0% (26/525) 
in the NAC group and 4.4% (23/527) in the surgery group. Combined data showed no significant differ-
ence in postoperative mortality between the two arms (RR = 1.13, 95% CI: 0.66–1.93; P = 0.66). Similar 
results were obtained when a random effect model was used (RR = 1.09, 95% CI = 0.63–1.90; P = 0.75) 
(Supplemental Fig. 2).
Recurrence and metastasis. As showed in Fig.  4, the rate of distant metastasis was 30.3% in the 
PC arm and 42.6% in the surgery arm, with an RR of 0.72 (95% CI: 0.59–0.87; P = 0.001), showing 
a significant reduction in distant metastasis associated with PC over surgery. Significant advantage in 
loco-regional recurrence of PC arm was not reached (RR = 0.80; 95% CI: 0.59–1.07; P = 0.132). In the 
trial comparing NAC with surgery alone16, neither the loco-regional recurrence rate (RR = 0.43, 95% CI: 
0.02–8.01; P = 0.571) nor the distal metastasis rate (RR = 2.47, 95% CI: 0.72–8.45; P = 0.151) showed any 
statistical significance.
Publication Bias. The contour-enhanced funnel plot showed evidence of asymmetry (Fig.  5). 
However, the darker-shaded area, where “missing studies” would be expected in order to correct for vis-
ually detected asymmetry, lay within the significant regions of the plot. This would suggest that the asym-
metry observed might not be due to publication bias based on statistical significance. This notion was 
confirmed by a non-significant Egger’s test (bias coefficient = − 0.25, 95% CI: − 3.43 to 2.92; P = 0.856). 
Furthermore, applying the trim-and-fill method to this meta-analysis by using the metatrim command 
resulted in no studies needing to be filled.
Discussion
Based on the huge success of the MAGIC study, NAC has recently become another research hotspot (in 
addition to surgery and AC) for treatment of operable gastric cancer. Unfortunately, the trials comparing 
NAC plus surgery with surgery alone have failed to demonstrate any survival benefit in operable gastric 
cancer patients19,20. The related meta-analyses also failed to find a correlation, and there were some weak-
nesses in the inclusion criteria and statistical analyses in those studies9–11. In the present meta-analysis, 
we discovered convincingly that the treatment strategy of PC plus surgery in the treatment arm verified 
the statistical significance of the effect on improving OS in contrast to AC following surgery treatment 
in the control arm. In other words, the addition of NAC to AC (i.e. PC) made the death hazard in oper-
able Asian gastric cancer patients fall dramatically by more than half (HR = 0.48, 95% CI: 0.35–0.67; 
P < 0.001) compared with AC alone. While the HR of OS for AC over surgery in gastric cancer was much 
higher (0.82, 95% CI: 0.76–0.90; P < 0.001), as pooled in another classical meta-analysis by Paoletti et 
al.30. However, the pooled HR of the two trials comparing NAC plus surgery with surgery alone did not 
show any OS advantage for NAC. The great diversity between these outcomes shows that NAC alone 
Figure 3. Pooled analysis of local control effect of NAC for gastric cancers. (A) Forest plot showing the 
R0 resection rate of gastric cancer patients in eight NAC-containing RCTs. The relative risk (RR) with 95% 
CI for effect of treatment on R0 rate is shown on a logarithmic scale using a fixed effect model. Subgroup 
analysis was based on geographic regions. (B) Forest plot showing the down-staging effect of gastric cancer 
patients in eight NAC-containing RCTs. The RR with 95% CI for effect of treatment on down-staging is 
shown on a logarithmic scale using a random effect model.
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Figure 4. Forest plot showing loco-regional recurrence and metastasis of gastric cancer patients in three 
NAC-containing RCTs. 
Figure 5. Contour-enhanced funnel plot for meta-analysis of RCTs of NAC for resectable gastric 
cancers. The “missing” studies would be expected to lie in areas of high statistical significance (i.e. the 
darker-shaded area).
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is not enough and AC alone is not good enough to definitely improve the OS in patients with gastric 
cancer, for NAC plus surgery is not superior to surgery alone, and AC is inferior to PC, as discovered 
in this meta-analysis.
It should be noted that the three trials suggesting the superiority of PC over AC were all carried out 
in east Asia where AC following D2 gastrectomy is a standard therapeutic strategy based on two pivotal 
RCTs (ACTS-GC5 and CLASSIC7), but NAC for resectable gastric cancer is not accepted as widely as it 
is in Europe. A large number of Asian doctors do not have a clear idea of the effects of NAC. They tend 
to be suspicious of its effect and side effect. Our present results provide hard evidence to help dispel 
the doubts about NAC and to promote the implementation of NAC in combination with AC to achieve 
better survival outcomes safely in gastric cancer patients, without significantly increasing the postoper-
ative morbidity and mortality. Moreover, it is necessary to conduct large RCTs comparing PC with AC 
in gastric cancer to validate our conclusion. The results of such studies might change the current chem-
otherapeutic strategy and lead to further survival advantage for gastric cancer patients. Coincidentally, 
our proposal is consistent with the recent viewpoints of some Asian scholars31,32.
It is not unexpected that the other two trials conducted in Europe comparing NAC with surgery 
obtained negative results in our survival analysis. MAGIC3, FFCD970327, and several recent studies8,33 
have all produced results strongly suggesting that PC rather than surgery alone is beneficial for resectable 
gastric cancer. Thus, we propose that a combined strategy of NAC plus AC is as yet the best treatment for 
operable gastric cancer. Treatment strategy in both Asia and Europe appear to have reached consensus on 
this issue. However, it should be noted that in Europe results are only available for the comparison of PC 
with surgery, and not for the comparison of PC with AC3,26,27. Thus, large RCTs should also be conducted 
in Europe to address this question. In addition, there is no Asian trial focusing on the effectiveness on 
NAC plus surgery versus surgery alone yet. However, considering the wide acceptance of AC in Asia 
and the negative results of NAC alone in Europe, it might make little sense—and would hardly meet the 
ethical requirements to perform such research in Asia.
Regimens of all the trials included in our analysis contained fluorouracil (5-FU) or its derivatives, 
and some contained platinum, anthracycline or taxane. Based on the results of subgroup analysis on 
NAC regimens, we concluded that gastric cancer patients might benefit from NAC regimens containing 
platinum and fluorouracil. Unfortunately, the trials included in this meta-analysis did not contain the 
current generally-accepted regimens such as FOLFOX, XELOX, or S-1. A Japanese phase-II clinical trial 
suggested that a fluorouracil-free TC regimen (paclitaxel and cisplatin) for NAC might also be effective 
and safe in locally advanced gastric cancers34. As it stands, large RCTs are still needed to confirm the 
effectiveness and relevance of different regimens of NAC.
In terms of PFS, the only trial in this meta-analysis to compare NAC with surgery obtained a nega-
tive result20. The pooled HR for PFS in two other trials comparing PC with surgery was 0.66 (95% CI: 
0.55–0.78; P < 0.001)3,27, which was much lower than that for pure AC versus surgery (HR = 0.82; 95% 
CI: 0.75–0.90; P < 0.001)30. When analyzing horizontally, we found that PC was superior to AC or NAC 
alone in improving PFS for resectable gastric cancer patients, which was consistent with the result for 
OS. The small number of studies included showed the need for large-scale RCTs for comparison of PC 
with AC in PFS.
The R0 resection rate is a crucial factor related to prognosis, and there was also controversy on the 
effect of NAC to increase it9,11,35. We found that NAC significantly improved the R0 resection rate, and 
subgroup analysis revealed that the R0 resection rate was significantly improved in Asian countries but 
not in non-Asian regions. This discrepancy might result from differences between regions in surgical 
procedures, in the extent of resection, or in pathological examinations. Tumor stage is another signif-
icant prognostic factor for gastric cancer patients. D’Ugo et al. reported that 3-year survival of gastric 
cancer patients after NAC was significantly related to tumor down-staging, and the patients with suc-
cessful R0 resections saw an improvement in survival36. Because the baseline of the NAC group and the 
control group was balanced in our study, the pathological examination after surgery could reflect the 
down-staging effect of NAC. The percentages of both T0-2 and N0 staging were significantly higher in 
the NAC group indicating a down-staging effect of NAC for locally advanced gastric cancer. This was 
consistent with the work of Li et al. who showed that NAC significantly reduces tumor stage in pT0-2 
(OR = 1.71, 95% CI: 1.26–2.33)9.
On the whole, NAC alone could down-stage the primary tumor and improve the R0 resection rate 
but this might not translate into a long-term survival benefit. However, NAC followed by AC (i.e., PC) 
could significantly increase the survival advantage in resectable gastric cancer patients. So, why would 
this distinction exist? We combined the available response rates of NAC in six trials19,20,22,24,25,28 and 
found that the pooled response rate of NAC was 0.48 (95% CI: 0.34–0.62; Fig. 6), i.e., almost half of the 
patients showed no response to NAC. Blank et al. has reported a positive relationship between response 
rate to NAC and R0 resection rate, and even median OS37. In this meta-analysis, the R0 resection rates, 
down-staging of primary tumor or lymph node in the NAC arm were increased by 7.3%, 6.7%, and 
10.2%, respectively. These improvements were significant but limited—possibly related to the limitation 
of the response to NAC. Thus, the possible limitation of NAC might be overcome by the following AC, 
in light of the positive effect of AC in improving the survival of gastric cancer patients. Furthermore, 
we have found that PC can significantly reduce the rate of distant metastasis in gastric cancer patients, 
while NAC alone can’t. This might be related to the effect of AC in preventing recurrence and metastasis 
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although clinical trials have shown divergent results on this issue38–43. We speculate, therefore, that PC 
might be more effective in controlling recurrence and metastasis of operable gastric cancer than NAC 
alone, and this is in accordance with the outcomes of OS and PFS. However, this speculation should be 
verified by further study because of its limitation of scale and geographic region. In addition, a NAC 
regimen with poor effect could be substituted by another one during AC period24,25. The modifying 
effect could to some extent compensate for the limitations of NAC and improve the overall efficacy. The 
combination of NAC and AC could, therefore, lead to a synergistic effect, and this means that PC could 
maximize the survival benefit in operable gastric cancer patients.
Chemoradiotherapy is recommended as the standard treatment strategy for locally advanced gastric 
cancer in the US based on the US Intergroup-0116 trial4. In Asia, the ARTIST study suggested that post-
operative radiotherapy might not be necessary in combination with AC after D2 gastrectomy, but it did 
significantly prolong DFS in patients with pathological lymph node-positive disease44. A Chinese study 
showed that adjuvant chemoradiotherapy (ACR) was associated with an increase in the median duration 
of recurrence-free survival compared to AC, and that this effect occurred regardless of whether or not 
there was lymph node metastasis45. In western countries, a prospective RCT (CRITICS)46 is being carried 
out with the intention of comparing NAC plus ACR with PC in gastric cancer patients. However, there is 
no large RCT focusing on comparison of PC with ACR. It is urgent that large RCTs comparing PC with 
radiotherapy-containing treatment be performed to find the optimal multimodal treatment strategy for 
operable gastric cancers.
This meta-analysis has the following limitations. First, the regimens used in the trials varied greatly. 
Second, the quantity and quality of RCTs comparing NAC with surgery were limited making it less prac-
tical to analyze the effect on OS of NAC alone. Third, the trial by Yonemura22 enrolled some stage-IV 
gastric cancer patients, and Nio24 used randomized consent design in his trial (i.e. grouping was partly 
decided by the patients). This resulted in a baseline that was not well balanced and which might account 
for underestimation of the effect of NAC.
In conclusion, our meta-analysis supports the use of PC in Asian countries as well as in Europe. We 
also suggest that large international RCTs comparing PC with AC should be conducted to further verify 
the effect of PC in operable gastric cancer patients. Current chemotherapy regimens are recommended in 
these trials and could be adjusted at the AC stage according to the response to NAC. It is also necessary 
to perform large RCTs comparing PC with radiotherapy-containing treatment to find the optimal mul-
timodal treatment strategy for operable gastric cancers. The final results will help to guide and change 
clinical practice in gastric cancer treatment.
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